Evolving Considerations in the Management of HER2-Positive Advanced Breast Cancer: Individualized Treatment for Improved Clinical and Economic Outcomes

Evolving Considerations in the Management of HER2-Positive Advanced Breast Cancer: Individualized Treatment for Improved Clinical and Economic Outcomes is organized by National Association of Managed Care Physicians (NAMCP).,,This activity is valid from June 1, 2022, to August 1, 2023,,Description:,Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the American Cancer Society, an estimated 281,550 new cases of invasive breast cancer are to be diagnosed in women in the United States during 2021. The incidence in women in the United States is 1 in 8 (about 12 percent). About 46,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells. In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. Additionally, in the later stages of HER2+ disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the HER2+ metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment selection must be individualized based upon patient- and tumor-specific factors, as well as safety and efficacy profile of available agents, with an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life.,,Upon completion of this activity, participants will be able to:,• Discuss the clinical and economic burden of HER2-positive breast cancer in terms of relative survival, mortality, drug utilization, adverse event management, and hospitalizations,• Review current guidelines, newer options, and best practices for HER2-positive breast cancer,• Analyze the efficacy, safety and mechanisms of action of new and emerging therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, for the treatment of HER2-positive advanced breast cancer,• Explore the role of antibody-drug conjugates and tyrosine kinase inhibitors in the treatment of patients with HER2-positive advanced breast cancer and those with brain metastases,• Examine strategies for anticipating, recognizing, and managing adverse events of new and emerging therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, in HER2-positive advanced breast cancer,• Employ oncology clinical pathways as a tool to assist in access and resource utilization for HER2-positive breast cancer